HKMPY (Hikma Pharmaceuticals) Margin of Safety % (DCF Earnings Based): 31.51% (As of Jun. 27, 2026)


HKMPY Hikma Pharmaceuticals PLC HKMPY
87 GF Score
Price $41.23
GF Value $56.75
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Hikma Pharmaceuticals HKMPY 87 Margin of Safety % (DCF Earnings Based) is 31.51% as of Jun. 27, 2026. GuruFocus rates HKMPY with a GF Score™ of 87/100 and a GF Value™ of $56.75 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-06-27), Hikma Pharmaceuticals's Predictability Rank is 3.5-Stars. Hikma Pharmaceuticals's intrinsic value calculated from the Discounted Earnings model is $60.20 and current share price is $41.23. Consequently,

Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is 31.51%.

HKMPY vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hikma Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


HKMPY
87GF Score
Hikma Pharmaceuticals PLC HKMPY
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Margin of Safety % (DCF Earnings Based) Calculation

Hikma Pharmaceuticals's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)=(Intrinsic Value: DCF (Earnings Based)-Current Price)/Intrinsic Value: DCF (Earnings Based)
=(60.20-41.23)/60.20
=31.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

What does a Margin of Safety % (DCF Earnings Based) of 31.51% mean?
Hikma Pharmaceuticals (HKMPY) has a Margin of Safety % (DCF Earnings Based) of 31.51% as of Jun. 27, 2026. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Hikma Pharmaceuticals.
Is Hikma Pharmaceuticals' Margin of Safety % (DCF Earnings Based) too high?
Hikma Pharmaceuticals' current Margin of Safety % (DCF Earnings Based) is 31.51%. Overall, Hikma Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Margin of Safety % (DCF Earnings Based) compare to ZTS and UTHR?
Hikma Pharmaceuticals' Margin of Safety % (DCF Earnings Based) of 31.51% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF Earnings Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF Earnings Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF Earnings Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF Earnings Based) mean?
A high Margin of Safety % (DCF Earnings Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Hikma Pharmaceuticals. Hikma Pharmaceuticals's current Margin of Safety % (DCF Earnings Based) is 31.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPY) is currently considered Modestly Undervalued. The stock's GF Value™ is $56.75, compared to a current price of $41.23 — trading 27.3% below its estimated fair value. The current Margin of Safety % (DCF Earnings Based) is 31.51%. Hikma Pharmaceuticals' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF Earnings Based) calculated?
Margin of Safety % (DCF Earnings Based) is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPY), the current Margin of Safety % (DCF Earnings Based) is 31.51% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (HKMPY) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $41.23 is trading 27.3% below its estimated GF Value™ of $56.75. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKMPY:

  • Margin of Safety % (DCF Earnings Based): 31.51%
  • GF Value™: $56.75 vs. price of $41.23 (27.3% below fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the HKMPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
87GF Score

Get the complete analysis for HKMPY

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.23
Price
$56.75
GF Value